This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
Stocks · News reference
Sol-Gel Technologies Announces Last Patient Last Visit In Pivotal Phase 3 Trial Of SGT-610 For Gorlin Syndrome; Says Top-Line Results On Track For Late November
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cantor Fitzgerald Initiates Coverage On Sol-Gel Technologies with Overweight Rating
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Sol-Gel Technologies (NASDAQ:SLGL) with a Overweight rating.
SolGel Technologies (SLGL) Upgraded to Buy: Here's Why
Sol-Gel Technologies Ltd. (SLGL) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's Zacks Consensus Estimate has increased 41.9% over the past three months, positioning it in the top 20% of Zacks-covered stocks for estimate revisions. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation.